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1. INTRODUCTION {#rth212071-sec-0006}
===============

Beside clinical symptoms, the diagnosis of antiphospholipid syndrome (APS) is based on the presence of persistent antiphospholipid antibodies (aPL). The three main cornerstone antibodies are anticardiolipin (aCL) IgM/IgG, anti‐beta‐2 glycoprotein 1 antibodies (aβ2GPI) IgM/IgG, and lupus anticoagulant (LAC). Among many challenges in aPL measurement, the pre‐analytical conditions may influence test results.[1](#rth212071-bib-0001){ref-type="ref"}, [2](#rth212071-bib-0002){ref-type="ref"} Following the Standardization subcommittee (SSC) of the international society of thrombosis and haemostasis (ISTH) recommendations, FTC should be avoided for all aPL.[3](#rth212071-bib-0003){ref-type="ref"}, [4](#rth212071-bib-0004){ref-type="ref"} In contrast to the effect of freeze‐thawing in phospholipid‐dependent clotting assays used for LAC, there is little scientific literature for solid phase assays (SPA).[5](#rth212071-bib-0005){ref-type="ref"} However, APL testing is mainly performed in batch due to the potential negative influence of pre‐analytical variables, such as repeated FTC, on test results.

Evaluating the effect of repeated FTC on aCL IgM/IgG and aβ2GPI IgM/IgG could generate practical benefits for routine testing. Another useful application could be the use of stored samples for research and method evaluations.

2. METHODS {#rth212071-sec-0007}
==========

Patient plasmas (n = 42) were selected based on routine results to cover a wide titer range for all four APL, and on availability of an unthawed aliquot (Table [1](#rth212071-tbl-0001){ref-type="table"}).

###### 

Routine results for all selected patient samples (n = 42) stored in the routine archive

               Negative   Around Cut off   Positive   Strong positive                            
  ------------ ---------- ---------------- ---------- ----------------- --------- --- ---------- ----
  aCL IgG      3‐12       8                21‐34      6                 53‐54     3   103‐480    10
  aCL IgM      2‐18       7                22‐27      4                 52‐70     7   104‐2330   6
  aβ2GPI IgM   3‐9        7                21‐48      8                 54‐88     3   107‐2705   6
  aβ2GPI IgG   11‐18      9                23‐97      12                119‐186   4   213‐3153   12

aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.
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Citrated plasma was frozen after double centrifugation.[3](#rth212071-bib-0003){ref-type="ref"} Samples were collected between 2012 and 2017. First analysis of each included sample was performed on aliquot not thawed before. Further, samples were analyzed on five consecutive days with an additional, standardized FTC every day (Figure [1](#rth212071-fig-0001){ref-type="fig"}). All analysis were performed by an automated chemiluminescent assay (HemosIL AcuStar, Instrumentation Laboratory‐Werfen, Bedford, MA, USA) using the same reagent lot for each parameter during the study.

![Timelaps studydesign \*Thawing (37°C water bath 5 minutes); \*^\*^Start analysis (every day in same order); \*^\*\*^Freezing of all samples at −20°C](RTH2-2-366-g001){#rth212071-fig-0001}

Statistical analysis was done in Medcalc (MedCalc Statistical Software version 16.4.3 (MedCalc Software bvba, Ostend, Belgium). A Mann‐Withney test for statistical differences (*P *\<* *.05) between the first and following FTC was performed. If no statistical difference was obtained after five FTCs, a concordance correlation coefficient (CCC) was calculated.

3. RESULTS AND DISCUSSION {#rth212071-sec-0008}
=========================

To exclude long term storage as a potential source of degradation, all aPL titers after one FTC were compared with the original results (initially also obtained after one FTC). No significant differences between these results were observed. An interesting feature of these results, knowing that some of these samples were already stored for 5 years, is the stability over time. Having a closer look at samples stored frozen for more than 2 years, no significant difference was seen between the initial results and the results after one FTC in the current study. The sample results, 8 for aCL IgG, aCL IgM aβ2GPI IgM, and 13 for aβ2GPI IgG, showed an excellent correlation coefficient (0.94‐0.99) between the initial results and the result after one FTC obtained in this study. Due to the limited number of samples stored more than three years, no useful statistical analysis could be performed to confirm an even longer stability.

After five FTC, none of the samples degraded from positive to negative and no false positive results were seen. Also, no significant titer changes (defined as \> 10%) were seen after five FTC. Between the first and following repeated FTCs a Mann‐Withney test was performed for all aPL to look for statistical significant differences in titer (Table [2](#rth212071-tbl-0002){ref-type="table"}). Even after five FTC none of the aPL tested gave a significant difference in results. A correlation between the titers was calculated and illustrated in Figure [2](#rth212071-fig-0002){ref-type="fig"}, showing graphically and mathematical, the good correlation for all four aPL with a CCC between 0.98 and 1.

###### 

Overview of Mann‐Withney test results between the first and following freeze thaw cycle

               Samples   FTC1 med(IQR)   FTC2 med (IQR)   *P*‐value (FTC1‐2)   FTC3 med (IQR)   *P*‐value (FTC1‐3)   FTC4 med (IQR)   *P*‐value (FTC1‐4)   FTC5 med (IQR)   *P*‐value (FTC1‐5)
  ------------ --------- --------------- ---------------- -------------------- ---------------- -------------------- ---------------- -------------------- ---------------- --------------------
  aCL IgG      26        30(8‐93)        32 (13‐263)      .8692                33(13‐274)       .7418                35(147‐237)      .7349                34(13‐276)       .7143
  aCL IgM      24        55(13‐87)       57(11‐88)        .8528                58(11‐90)        .765                 59(11‐86)        .7259                57(8‐76)         .8481
  aβ2GPI IgM   25        31(8‐93)        28(9‐98)         .8234                31(8‐99)         .6908                29(9‐102)        .7784                31(8‐81)         .7949
  aβ2GPI IgG   37        74(22‐676)      73(18‐724)       .9354                79(15‐694)       .8642                74(11‐748)       .9058                74(13‐723)       .9551

aCL, anticardiolipin; aβ2GPI, anti‐beta 2 glycoprotein I.

John Wiley & Sons, Ltd

![The CCC calculated between first and fifth FTC are graphically shown. Values above 200 U/mL are disregarded in the graph (for visual purposes), but were included in the concordance correlation coefficient calculation and showed no significant difference with values below 200 IU/ml aCL, anticardiolipin; aβ2GPI, anti‐beta‐2 glycoprotein 1; CCC, concordance correlation coefficient; FTC, freeze‐thaw cycle](RTH2-2-366-g002){#rth212071-fig-0002}

Considering the high CCC, we could exclude a significant inter‐run variability as potential influencing factor on variability of titers. For each sample, a coefficient of variation (CV) was calculated using the test result after each FTC. Comparing the median CV value (for each aPL divided in four categories as described in Table [1](#rth212071-tbl-0001){ref-type="table"}) with results obtained from quality control (QC) material no significant difference was found. All median sample CV values varied between 4 and 15.6% comparing to the QC CV values of these runs, between 2.3‐13.9%. These results confirm the stable character of the antibodies and the limited effect of FTC.

Furthermore, 4 months later, a selection of these samples with sufficient sample volume, were additionally thawed and analyzed using another batch of reagent. No significant differences were observed between first FTC and these results. As a final test, these samples were also analyzed on a second analyzer of the same type, also resulting in non‐significant differences. Correlating results after the first FTC on analyzer 1 and results after the sixth FTC on a second analyzer a concordance correlation coefficient was found, depending on the antibody, between 0.91‐0.98. Comparing both analyzers, with a sample size varying between 13 and 23 samples, an excellent correlation coefficient of 0.99 for each antibody was found, confirming the robustness of this automated systems.[6](#rth212071-bib-0006){ref-type="ref"}

aPL are very heterogeneous group of antibodies. The small sample size, although covering a broad titer range, may be seen as a limitation of this study. Also, all tests were performed using one and the same analytical platform. Other test systems are known to be less robust suffering from lab to lab variation or high between‐run variation.[6](#rth212071-bib-0006){ref-type="ref"}, [7](#rth212071-bib-0007){ref-type="ref"} Using this automated system excludes these variables, making it possible to exclusively evaluate the effect of freeze‐thaw cycles.

4. CONCLUSION {#rth212071-sec-0009}
=============

We evaluated the stability of aPL titers after several FTC. aCL and aβ2GPI IgG and IgM, over a broad titer range including samples around the cut‐off value, are stable over time and after repeated FTC. With this study, we excluded this pre‐analytical factor as source for variability in aPL titer measured by chemiluminescent assays.

AUTHOR CONTRIBUTIONS {#rth212071-sec-0010}
====================

KMJ Devreese conceived the study idea and supervised, consulted, and corrected the study design, statistical analysis and manuscript. KR Maelegheer developed the study design, performed practical and statistical analysis, and wrote the manuscript.

RELATIONSHIP DISCLOSURE {#rth212071-sec-0011}
=======================

No conflicts of interest to declare.
